Zhong et al. considered mitochondrial ALDH2 a promising therapeutic target for ALD, based on their finding that a selective small-molecule ALDH2 activator, N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide (Alda-1), can accelerate aldehyde clearance and reverse hepatic steatosis and apoptosis in mice through pharmacological activation of ALDH2 59. Here, ALDH2 is linked to Hepatic steatosis.